This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kistorp, C. Search for Related Content PubMed PubMed Citation Articles by Kistorp, C. Related Collections Risk Factors Chronic ischemic heart disease Epidemiology

(Circulation. 2006;114:184-186.)
© 2006 American Heart Association, Inc.

Editorial

Risk Stratification in Secondary Prevention

Advances in Multimarker Profiles, or Back to Basics?

Caroline Kistorp, MD, PhD

From the Department of Cardiology and Endocrinology, Frederiksberg University Hospital, Copenhagen, Denmark.

Correspondence to Dr Caroline Kistorp, Department of Cardiology and Endocrinology, Frederiksberg University Hospital, 57 Nordre Fasanvej, DK-2000 Frederiksberg, Denmark. E-mail cnkistorp@dadlnet.dk

Key Words: Editorials • arteriosclerosis • epidemiology • inflammation • biomarkers • risk stratification • secondary prevention

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Prevention and risk management of atherosclerotic vascular disease remain major health challenges. Coronary heart disease (CHD) and other cardiovascular diseases remain the primary causes of mortality and morbidity in developed countries. Improvement of risk stratification by identification of new biomarkers has been extensively investigated in both primary and secondary clinical settings in the past decade. A substantial number of biomarkers, representing various stages of atherogenesis and impaired cardiac function, have been evaluated against modifiable traditional risk factors, such as cholesterol, blood pressure, smoking status, and diabetes.^1–4 However, whether these various biomarkers add incremental prognostic information to that provided by traditional risk factors is still controversial, and the clinical implications of "high" biomarker levels have yet to be determined. A multimarker strategy of combining biomarkers may theoretically help clinicians to stratify subjects into risk categories, but data on this subject are scarce.^5,6

Article p 201

In this issue of Circulation, Blankenberg and coauthors⁷ evaluate the prognostic value of multiple biomarkers compared with that of traditional risk factors on cardiovascular events in a large subgroup of the Heart Outcomes Prevention Evaluation (HOPE) study. The biomarkers examined cover a broad range of inflammation and endothelial activation, including C-reactive protein (CRP) and cellular adhesion molecules, as well as the cardiac neurohormone N-amino terminal of the prohormone brain natriuretic peptide (NT-proBNP). The well-known HOPE study was a randomized, clinical trial investigating ramipril and vitamin E in patients with CHD, peripheral vascular disease, diabetes, or previous stroke. A total of 3199 patients with available blood . . . [Full Text of this Article]

This article has been cited by other articles:

				T. Mueller, B. Dieplinger, W. Poelz, G. Endler, O. F. Wagner, and M. Haltmayer Amino-Terminal Pro-B-Type Natriuretic Peptide as Predictor of Mortality in Patients with Symptomatic Peripheral Arterial Disease: 5-Year Follow-Up Data from the Linz Peripheral Arterial Disease Study Clin. Chem., January 1, 2009; 55(1): 68 - 77. [Abstract] [Full Text] [PDF]

				S. Haugen, I. P. Casserly, J. G. Regensteiner, and W. R. Hiatt Risk assessment in the patient with established peripheral arterial disease Vascular Medicine, November 1, 2007; 12(4): 343 - 350. [Abstract] [PDF]

				D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]